Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GHDX Genomic Health (GHDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Genomic Health Stock (NASDAQ:GHDX) 30 days 90 days 365 days Advanced Chart Ad Wealthpin ProVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. Get Genomic Health alerts:Sign Up Key Stats Today's Range$63.44▼$63.4450-Day Range$63.44▼$69.7952-Week Range$50.77▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Read More… Receive GHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomic Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GHDX Stock News HeadlinesEarly genomic profiling improves cancer treatment outcomesNovember 13, 2024 | msn.comNew insights on the association between genes, gut microbiota, and mental healthNovember 1, 2024 | msn.comVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. December 23, 2024 | Wealthpin Pro (Ad)Most patients with mitochondrial disease can be diagnosed via genomic sequencing, study saysOctober 31, 2024 | msn.comFujita Health University and BostonGene Expand Access to Genomic Cancer Testing with Tumor Portrait™ at Haneda ClinicOctober 22, 2024 | tmcnet.comComplex genomic variants are related to psychiatric diseases, study findsOctober 22, 2024 | msn.comSkylineDx reports data from melanoma genomic assay in US trialOctober 15, 2024 | msn.comNew genomic surveillance tools could help efforts to eliminate damaging parasitic infectionsOctober 3, 2024 | msn.comSee More Headlines GHDX Stock Analysis - Frequently Asked Questions How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) released its earnings results on Monday, November, 11th. The medical research company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.11. Genomic Health had a net margin of 12.81% and a trailing twelve-month return on equity of 19.62%. What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genomic Health investors own include Revance Therapeutics (RVNC), Horizon Therapeutics Public (HZNP), Illumina (ILMN), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX) and Exelixis (EXEL). Company Calendar Last Earnings11/11/2019Today12/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:GHDX CUSIP37244C10 CIK1131324 Webwww.genomichealth.com Phone650-556-9300FaxN/AEmployees829Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.05 Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/ANet Income$25.68 million Net Margins12.81% Pretax MarginN/A Return on Equity19.62% Return on Assets14.89% Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Miscellaneous Outstanding Shares37,590,000Free FloatN/AMarket Cap$2.38 billion OptionableOptionable Beta0.90 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:GHDX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genomic Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.